心血管病防治知识(下半月)
心血管病防治知識(下半月)
심혈관병방치지식(하반월)
XINXUEGUANBING FANGZHI ZHISHI
2014年
12期
14-17
,共4页
周波%徐细平%冯小坚%潘港
週波%徐細平%馮小堅%潘港
주파%서세평%풍소견%반항
小剂量合贝爽%培哚普利%老年单纯收缩期高血压%临床疗效
小劑量閤貝爽%培哚普利%老年單純收縮期高血壓%臨床療效
소제량합패상%배타보리%노년단순수축기고혈압%림상료효
Low-dose Herbesser%Perindopril%Isolated systolic hypertension in the elderly%Clinical efficacy
目的:探讨小剂量合贝爽联合培哚普利治疗老年单纯收缩期高血压的临床疗效。方法选取2012年8月至2014年8月之间在我院接受治疗的120例老年单纯收缩期高血压患者为观察对象,随机均分为三组,分别接受小剂量合贝爽、培哚普利、小剂量合贝爽联合培哚普利治疗12周,观察治疗前后三组收缩压、舒张压、脉压差、尿微量白蛋白变化,同时观察三组患者治疗后不良反应。结果联合治疗组的疗效显著高于小剂量合贝爽组和培哚普利组,三组患者的血压均显著下降与治疗前对比(P<0.05);联合治疗组患者的收缩压和脉压差与小剂量合贝爽组对比(P<0.05);与培哚普利组对比,脉压差改善明显(P<0.05);收缩压改善程度对比(P>0.05)。三组患者的舒张压水平对比(P>0.05);与治疗前对比,三组患者的尿微量白蛋白水平显著降低(P<0.05);联合治疗组与小剂量合贝爽组及培哚普利组比较,尿微量白蛋白水平均显著降低,差异具有统计学意义(P<0.05)。三组患者治疗后均未出现明显不良反应。结论老年单纯收缩期高血压患者接受小剂量合贝爽联合培哚普利治疗,明显降低患者收缩压及脉压差,降低尿微量尿蛋白,服药简便,安全有效。
目的:探討小劑量閤貝爽聯閤培哚普利治療老年單純收縮期高血壓的臨床療效。方法選取2012年8月至2014年8月之間在我院接受治療的120例老年單純收縮期高血壓患者為觀察對象,隨機均分為三組,分彆接受小劑量閤貝爽、培哚普利、小劑量閤貝爽聯閤培哚普利治療12週,觀察治療前後三組收縮壓、舒張壓、脈壓差、尿微量白蛋白變化,同時觀察三組患者治療後不良反應。結果聯閤治療組的療效顯著高于小劑量閤貝爽組和培哚普利組,三組患者的血壓均顯著下降與治療前對比(P<0.05);聯閤治療組患者的收縮壓和脈壓差與小劑量閤貝爽組對比(P<0.05);與培哚普利組對比,脈壓差改善明顯(P<0.05);收縮壓改善程度對比(P>0.05)。三組患者的舒張壓水平對比(P>0.05);與治療前對比,三組患者的尿微量白蛋白水平顯著降低(P<0.05);聯閤治療組與小劑量閤貝爽組及培哚普利組比較,尿微量白蛋白水平均顯著降低,差異具有統計學意義(P<0.05)。三組患者治療後均未齣現明顯不良反應。結論老年單純收縮期高血壓患者接受小劑量閤貝爽聯閤培哚普利治療,明顯降低患者收縮壓及脈壓差,降低尿微量尿蛋白,服藥簡便,安全有效。
목적:탐토소제량합패상연합배타보리치료노년단순수축기고혈압적림상료효。방법선취2012년8월지2014년8월지간재아원접수치료적120례노년단순수축기고혈압환자위관찰대상,수궤균분위삼조,분별접수소제량합패상、배타보리、소제량합패상연합배타보리치료12주,관찰치료전후삼조수축압、서장압、맥압차、뇨미량백단백변화,동시관찰삼조환자치료후불량반응。결과연합치료조적료효현저고우소제량합패상조화배타보리조,삼조환자적혈압균현저하강여치료전대비(P<0.05);연합치료조환자적수축압화맥압차여소제량합패상조대비(P<0.05);여배타보리조대비,맥압차개선명현(P<0.05);수축압개선정도대비(P>0.05)。삼조환자적서장압수평대비(P>0.05);여치료전대비,삼조환자적뇨미량백단백수평현저강저(P<0.05);연합치료조여소제량합패상조급배타보리조비교,뇨미량백단백수평균현저강저,차이구유통계학의의(P<0.05)。삼조환자치료후균미출현명현불량반응。결론노년단순수축기고혈압환자접수소제량합패상연합배타보리치료,명현강저환자수축압급맥압차,강저뇨미량뇨단백,복약간편,안전유효。
Objective To investigate the clinical efficacy of low-dose Herbesser combined with perindopril in the treatment of isolated systolic hypertension (ICH) in the elderly. Methods One hundred and twenty elderly patients with ICH who were admitted to our hospital from August 2012 to August 2014 were randomly and equally divided into three groups. These groups received low-dose Herbesser, perindopril, and low-dose Herbesser combined with perindopril for 12 weeks, respectively. Systolic pressure, diastolic pressure, pulse pressure, and urinary albumin levels in the three groups were measured before and after treatment. Adverse reactions in the three groups were also observed after treatment. Results The efficacy of combined therapy was significantly better than that of low-dose Herbesser alone and perindopril alone. Blood pressure values in the three groups significantly decreased after treatment (P<0.05). Patients treated with combined therapy had significant improvements in systolic pressure and pulse pressure compared with those treated with low-dose Herbesser alone (P<0.05). Compared with those treated with perindopril alone, patients treated with combined therapy showed a significant improvement in pulse pressure (P<0.05), rather than systolic pressure (P>0.05). There was no significant difference in diastolic pressure between the three groups (P>0.05). Urinary albumin levels in the three groups decreased significantly after treatment (P<0.05). The combined therapy group had a significantly lower urinary albumin level after treatment compared with the low-dose Herbesser group and perindopril group (P<0.05). There were no obvious adverse reactions in the three groups after treatment. Conclusion Elderly patients with ICH have significantly reduced systolic pressure, pulse pressure, and urinary albumin levels after treatment with low-dose Herbesser combined with perindopril. This combined medication is simple, safe, and effective.